Abstract
Aging has become a major health care problem and socio-economic burden worldwide. Myocardial infarction (MI) is the major killer worldwide and coronary reperfusion is the major form of acute post-MI therapy. The aging population is increasing, and with it, morbidity and mortality due to impaired healing after ST-segment elevation MI (STEMI) and its consequences. Optimal healing of the wounded heart is critical for preservation of structural and functional integrity of the pumping chambers, survival, and a favorable outcome irrespective of age. Although STEMI is more prevalent in the elderly and impaired healing during aging may promote adverse remodeling and thereby jeopardize outcome, there is an information gap on post-STEMI healing and its therapy in the elderly. Current therapies during post-STEMI healing are aimed primarily at the < 65 age-group and preclinical studies tend to test drugs in mostly young animals. Therapies over the last decade have improved post-MI survival mainly in patients aged < 65 years. Novel healing-specific proteins may provide potential targets for improving healing and limiting adverse remodeling of the post-STEMI heart in the elderly, thereby improving outcome.
Keywords: Aging, ST-segment elevation myocardial infarction, ventricular remodeling, extracellular matrix, healing-specific proteins, secretory leucocyte protease inhibitor, osteopontin, secreted protein acidic and rich in cysteine
Current Drug Targets
Title: Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Volume: 9 Issue: 4
Author(s): Bodh I. Jugdutt
Affiliation:
Keywords: Aging, ST-segment elevation myocardial infarction, ventricular remodeling, extracellular matrix, healing-specific proteins, secretory leucocyte protease inhibitor, osteopontin, secreted protein acidic and rich in cysteine
Abstract: Aging has become a major health care problem and socio-economic burden worldwide. Myocardial infarction (MI) is the major killer worldwide and coronary reperfusion is the major form of acute post-MI therapy. The aging population is increasing, and with it, morbidity and mortality due to impaired healing after ST-segment elevation MI (STEMI) and its consequences. Optimal healing of the wounded heart is critical for preservation of structural and functional integrity of the pumping chambers, survival, and a favorable outcome irrespective of age. Although STEMI is more prevalent in the elderly and impaired healing during aging may promote adverse remodeling and thereby jeopardize outcome, there is an information gap on post-STEMI healing and its therapy in the elderly. Current therapies during post-STEMI healing are aimed primarily at the < 65 age-group and preclinical studies tend to test drugs in mostly young animals. Therapies over the last decade have improved post-MI survival mainly in patients aged < 65 years. Novel healing-specific proteins may provide potential targets for improving healing and limiting adverse remodeling of the post-STEMI heart in the elderly, thereby improving outcome.
Export Options
About this article
Cite this article as:
Jugdutt I. Bodh, Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets, Current Drug Targets 2008; 9 (4) . https://dx.doi.org/10.2174/138945008783954934
DOI https://dx.doi.org/10.2174/138945008783954934 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Mechanism of Carvedilol in Experimental Viral Myocarditis
Current Pharmaceutical Design Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry Pharmacology of TRP Channels in the Vasculature
Current Vascular Pharmacology Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety NTproBNP: An Important Biomarker in Cardiac Diseases
Current Topics in Medicinal Chemistry Editorial: (Thematic Issue: Novel Strategies for Cardiac Repair Post-Myocardial Infarction)
Current Pharmaceutical Design Atrial Fibrillation and Hypertension: “Quo Vadis”
Current Hypertension Reviews Takotsubo-Like Left Ventricular Dysfunction in an HIV-Infected Patient
Current HIV Research Hypothyroidism and Endothelial Function: A Marker of Early Atherosclerosis?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Meet Our Editorial Board Member:
Current Vascular Pharmacology MicroRNAs and Cardiac Conduction
Current Drug Targets Normal Ventricular Functional Reference Parameters on Magnetic Resonance Imaging in Healthy Children
Current Medical Imaging Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment
Current Medicinal Chemistry Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias
Current Cardiology Reviews